<DOC>
	<DOC>NCT00540228</DOC>
	<brief_summary>In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals' influenza vaccine administered in adults aged 18-64 years.</brief_summary>
	<brief_title>Study to Evaluate an Influenza Vaccine Candidate</brief_title>
	<detailed_description>The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Only subjects who the investigator believes that they can and will comply with the requirements of the protocol . A male or female between, and including, 18 64 years of age at the time of vaccination. Written informed consent obtained from the subject. Healthy subjects as established by medical history and clinical examination before entering into the study. If the subject is female, she must be of nonchildbearing potential or if she is of childbearing potential, she must have a negative pregnancy test, practice adequate contraception for 30 days prior to vaccination, and continue such precautions for 2 months after completion of the vaccination series. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. Chronic administration (defined as more than 14 days) of immunosuppressants or other immunemodifying drugs within three months prior to the first vaccine dose Administration of a vaccine not foreseen by the study protocol from 30 days before vaccination, up to 21 days after vaccination. History of hypersensitivity to a previous dose of influenza vaccine. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s) Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. Confirmed influenza infection within a year preceding the study start. Administration of an influenza vaccine within a year preceding the study start. Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. Pregnant or lactating female. Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a noninvestigational product Acute disease at the time of enrolment. History of chronic alcohol consumption and/or drug abuse. Female planning to become pregnant or planning to discontinue contraceptive precautions. Any condition which, in the opinion of the investigator, prevents the subject from participating in the study. History of administration of experimental/licensed vaccine containing squalene and/or tocopherol within the last 12 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza Vaccine</keyword>
</DOC>